As ferric citrate can function as both a phosphate binder and a source of iron, it can both decrease enteral phosphate absorption and improve iron status in CKD, thus targeting two of the mechanisms that increase FGF23 levels. This evidence concerns the gene FGF23 and chronic kidney disease.